Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma

S. B. Kaye, M. Clavel, P. Dodion, S. Monfardini, W. ten Bokkel-Huinink, D. T. Wagener, S. Gundersen, G. Stoter, J. Smith, J. Renard, M. van Glabbeke, F. Cavalli

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Phase II trials of flavone acetic acid have been performed in a total of 87 patients including 17 with advanced breast cancer, 23 with advanced colorectal cancer, 25 with advanced malignant melanoma and 22 with advanced head and neck cancer. Patients with colorectal cancer and melanoma had received no prior chemotherapy; in breast and head and neck cancer patients prior chemotherapy had been given with a median of 5 and 2 drugs respectively. The schedule used was a once-weekly regime, with a dose of 4.8 gms/m2 given as a 1 hour infusion, together with alkalinization (with i.v. sodium bicarbonate) given before and after FAA. Reassessment was performed after 6 weekly doses, although in 23 patients fewer than 6 doses were given, because of early disease progression in 15, and undue toxicity in 5. An additional 3 patients died within 72 hours of having received FAA and, although the precise cause of death in each case was not established, FAA toxicity could not be excluded. Treatment was generally manageable, the major manifestations of toxicity comprising uncomfortable warmth and flushes, nausea, diarrhoea, and visual complaints. Hypotension was also documented in 8 patients. No objective responses were seen in any of the patient sub-groups, although disease-stabilization was seen in 3 patients with breast cancer, 1 patient with advanced colorectal cancer, 2 patients with advanced melanoma and 4 patients with head and neck cancer. Further Phase II studies, using a higher dose of 8.6 gm/m2 over 6 hours once weekly, are currently in progress in Europe. However, Phase II studies to date indicate no antitumor activity of FAA given weekly as a single agent at the maximally tolerated dose over 1 hour.

Original languageEnglish
JournalInvestigational New Drugs
Volume8
Issue number1 Supplement
DOIs
Publication statusPublished - Mar 1990

Fingerprint

flavone acetic acid
Melanoma
Colon
Neck
Head
Breast Neoplasms
Head and Neck Neoplasms
Colorectal Neoplasms
Drug Therapy
Sodium Bicarbonate
Maximum Tolerated Dose

Keywords

  • advanced carcinoma
  • flavone acetic acid
  • phase II trial

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Kaye, S. B., Clavel, M., Dodion, P., Monfardini, S., ten Bokkel-Huinink, W., Wagener, D. T., ... Cavalli, F. (1990). Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. Investigational New Drugs, 8(1 Supplement). https://doi.org/10.1007/BF00171993

Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. / Kaye, S. B.; Clavel, M.; Dodion, P.; Monfardini, S.; ten Bokkel-Huinink, W.; Wagener, D. T.; Gundersen, S.; Stoter, G.; Smith, J.; Renard, J.; van Glabbeke, M.; Cavalli, F.

In: Investigational New Drugs, Vol. 8, No. 1 Supplement, 03.1990.

Research output: Contribution to journalArticle

Kaye, SB, Clavel, M, Dodion, P, Monfardini, S, ten Bokkel-Huinink, W, Wagener, DT, Gundersen, S, Stoter, G, Smith, J, Renard, J, van Glabbeke, M & Cavalli, F 1990, 'Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma', Investigational New Drugs, vol. 8, no. 1 Supplement. https://doi.org/10.1007/BF00171993
Kaye, S. B. ; Clavel, M. ; Dodion, P. ; Monfardini, S. ; ten Bokkel-Huinink, W. ; Wagener, D. T. ; Gundersen, S. ; Stoter, G. ; Smith, J. ; Renard, J. ; van Glabbeke, M. ; Cavalli, F. / Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. In: Investigational New Drugs. 1990 ; Vol. 8, No. 1 Supplement.
@article{59a19059a37441f0adeff01541cf9a1a,
title = "Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma",
abstract = "Phase II trials of flavone acetic acid have been performed in a total of 87 patients including 17 with advanced breast cancer, 23 with advanced colorectal cancer, 25 with advanced malignant melanoma and 22 with advanced head and neck cancer. Patients with colorectal cancer and melanoma had received no prior chemotherapy; in breast and head and neck cancer patients prior chemotherapy had been given with a median of 5 and 2 drugs respectively. The schedule used was a once-weekly regime, with a dose of 4.8 gms/m2 given as a 1 hour infusion, together with alkalinization (with i.v. sodium bicarbonate) given before and after FAA. Reassessment was performed after 6 weekly doses, although in 23 patients fewer than 6 doses were given, because of early disease progression in 15, and undue toxicity in 5. An additional 3 patients died within 72 hours of having received FAA and, although the precise cause of death in each case was not established, FAA toxicity could not be excluded. Treatment was generally manageable, the major manifestations of toxicity comprising uncomfortable warmth and flushes, nausea, diarrhoea, and visual complaints. Hypotension was also documented in 8 patients. No objective responses were seen in any of the patient sub-groups, although disease-stabilization was seen in 3 patients with breast cancer, 1 patient with advanced colorectal cancer, 2 patients with advanced melanoma and 4 patients with head and neck cancer. Further Phase II studies, using a higher dose of 8.6 gm/m2 over 6 hours once weekly, are currently in progress in Europe. However, Phase II studies to date indicate no antitumor activity of FAA given weekly as a single agent at the maximally tolerated dose over 1 hour.",
keywords = "advanced carcinoma, flavone acetic acid, phase II trial",
author = "Kaye, {S. B.} and M. Clavel and P. Dodion and S. Monfardini and {ten Bokkel-Huinink}, W. and Wagener, {D. T.} and S. Gundersen and G. Stoter and J. Smith and J. Renard and {van Glabbeke}, M. and F. Cavalli",
year = "1990",
month = "3",
doi = "10.1007/BF00171993",
language = "English",
volume = "8",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1 Supplement",

}

TY - JOUR

T1 - Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma

AU - Kaye, S. B.

AU - Clavel, M.

AU - Dodion, P.

AU - Monfardini, S.

AU - ten Bokkel-Huinink, W.

AU - Wagener, D. T.

AU - Gundersen, S.

AU - Stoter, G.

AU - Smith, J.

AU - Renard, J.

AU - van Glabbeke, M.

AU - Cavalli, F.

PY - 1990/3

Y1 - 1990/3

N2 - Phase II trials of flavone acetic acid have been performed in a total of 87 patients including 17 with advanced breast cancer, 23 with advanced colorectal cancer, 25 with advanced malignant melanoma and 22 with advanced head and neck cancer. Patients with colorectal cancer and melanoma had received no prior chemotherapy; in breast and head and neck cancer patients prior chemotherapy had been given with a median of 5 and 2 drugs respectively. The schedule used was a once-weekly regime, with a dose of 4.8 gms/m2 given as a 1 hour infusion, together with alkalinization (with i.v. sodium bicarbonate) given before and after FAA. Reassessment was performed after 6 weekly doses, although in 23 patients fewer than 6 doses were given, because of early disease progression in 15, and undue toxicity in 5. An additional 3 patients died within 72 hours of having received FAA and, although the precise cause of death in each case was not established, FAA toxicity could not be excluded. Treatment was generally manageable, the major manifestations of toxicity comprising uncomfortable warmth and flushes, nausea, diarrhoea, and visual complaints. Hypotension was also documented in 8 patients. No objective responses were seen in any of the patient sub-groups, although disease-stabilization was seen in 3 patients with breast cancer, 1 patient with advanced colorectal cancer, 2 patients with advanced melanoma and 4 patients with head and neck cancer. Further Phase II studies, using a higher dose of 8.6 gm/m2 over 6 hours once weekly, are currently in progress in Europe. However, Phase II studies to date indicate no antitumor activity of FAA given weekly as a single agent at the maximally tolerated dose over 1 hour.

AB - Phase II trials of flavone acetic acid have been performed in a total of 87 patients including 17 with advanced breast cancer, 23 with advanced colorectal cancer, 25 with advanced malignant melanoma and 22 with advanced head and neck cancer. Patients with colorectal cancer and melanoma had received no prior chemotherapy; in breast and head and neck cancer patients prior chemotherapy had been given with a median of 5 and 2 drugs respectively. The schedule used was a once-weekly regime, with a dose of 4.8 gms/m2 given as a 1 hour infusion, together with alkalinization (with i.v. sodium bicarbonate) given before and after FAA. Reassessment was performed after 6 weekly doses, although in 23 patients fewer than 6 doses were given, because of early disease progression in 15, and undue toxicity in 5. An additional 3 patients died within 72 hours of having received FAA and, although the precise cause of death in each case was not established, FAA toxicity could not be excluded. Treatment was generally manageable, the major manifestations of toxicity comprising uncomfortable warmth and flushes, nausea, diarrhoea, and visual complaints. Hypotension was also documented in 8 patients. No objective responses were seen in any of the patient sub-groups, although disease-stabilization was seen in 3 patients with breast cancer, 1 patient with advanced colorectal cancer, 2 patients with advanced melanoma and 4 patients with head and neck cancer. Further Phase II studies, using a higher dose of 8.6 gm/m2 over 6 hours once weekly, are currently in progress in Europe. However, Phase II studies to date indicate no antitumor activity of FAA given weekly as a single agent at the maximally tolerated dose over 1 hour.

KW - advanced carcinoma

KW - flavone acetic acid

KW - phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0025282726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025282726&partnerID=8YFLogxK

U2 - 10.1007/BF00171993

DO - 10.1007/BF00171993

M3 - Article

C2 - 2380021

AN - SCOPUS:0025282726

VL - 8

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1 Supplement

ER -